Results 281 to 290 of about 6,410,935 (343)
Some of the next articles are maybe not open access.
Current Pharmaceutical Design, 2013
Since the discovery of human immunodeficiency virus (HIV) as a causative agent of acquired immune deficiency syndrome (AIDS) various strategies were employed to counter its devastating actions. One such concept relies on the prevention of HIV entry into host's "competent" cells by means of compounds known as entry inhibitors.
Ewa D, Micewicz, Piotr, Ruchala
openaire +2 more sources
Since the discovery of human immunodeficiency virus (HIV) as a causative agent of acquired immune deficiency syndrome (AIDS) various strategies were employed to counter its devastating actions. One such concept relies on the prevention of HIV entry into host's "competent" cells by means of compounds known as entry inhibitors.
Ewa D, Micewicz, Piotr, Ruchala
openaire +2 more sources
2008
The entry of viruses into target cells involves a complex series of sequential steps, with opportunities for inhibition at every stage. Entry inhibitors exert their biological properties by inhibiting protein-protein interactions either within the viral envelope (Env) glycoproteins or between viral Env and host-cell receptors.
Tom, Melby, Mike, Westby
openaire +2 more sources
The entry of viruses into target cells involves a complex series of sequential steps, with opportunities for inhibition at every stage. Entry inhibitors exert their biological properties by inhibiting protein-protein interactions either within the viral envelope (Env) glycoproteins or between viral Env and host-cell receptors.
Tom, Melby, Mike, Westby
openaire +2 more sources
The HIV Entry Inhibitors Revisited
Current Medicinal Chemistry, 2006The new generation of antiviral drugs intended to counter HIV-1 entry into susceptible cells is emerging swiftly. The antiviral agents that inhibit HIV entry to the target cells (denoted as HIV entry inhibitors) are already in different phases of clinical trials.
J Thomas, Leonard, Kunal, Roy
openaire +2 more sources
Glycosidase Inhibitors as Potential HIV Entry Inhibitors?
Current Drug Metabolism, 2004A few alpha-L-fucosidase inhibitors and alpha-D-glucosidase inhibitors have shown in vitro anti-HIV activities, that have been attributed to their ability to inhibit HIV entry. The mechanism of action of inhibitors such as 1-deoxynojirimycin (1) is not clearly established.
Inmaculada, Robina +3 more
openaire +2 more sources
HIV-1 entry and entry inhibitors as therapeutic agents
Clinics in Laboratory Medicine, 2002Defining the mechanisms of HIV-1 entry has enabled the rational design of strategies aimed at interfering with the process. This article delineates what is currently understood about HIV-1 entry, as a window through which to understand what will likely be the next major group of antiretroviral therapeutics.
Linda D, Starr-Spires, Ronald G, Collman
openaire +2 more sources
Gold nanoparticles as an HIV entry inhibitor.
Current HIV Research, 2012Gold nanoparticles stabilized with polyethylene glycol were used to study their cytotoxicity and antiviral activity against HIV-1 in the laboratory. The HeLa-CD4-LTR-B-gal cell line was used with gold nanoparticles to determine the cell viability using luminescent assay.
S. Vijayakumar, S. Ganesan
semanticscholar +3 more sources
An Update in the Development of HIV Entry Inhibitors
Current Topics in Medicinal Chemistry, 2007HIV entry and fusion are two steps in the viral life cycle that can be targeted by several classes of antiviral drugs. The discovery of chemokines focused the attention on cellular coreceptors used by the virus for entering within cells, and to the various steps of such processes which are subject to interactions with small molecules.
S. Rusconi +3 more
openaire +3 more sources
HIV entry and fusion inhibitors
Expert Opinion on Emerging Drugs, 2004Human immunodeficiency virus (HIV) is a retrovirus that is the causative agent of acquired immunodeficiency syndrome (AIDS). Current HIV therapy is based on targeting two critical enzymes in the viral replication machinery: reverse transcriptase and a virally encoded protease. Although mortality rates due to HIV infection have been dramatically reduced,
openaire +2 more sources
Peptide-Based HIV Entry Inhibitors
2022The development of peptide-based HIV entry inhibitors has made an important contribution to the stock of anti-HIV drugs. In particular, the peptide-based anti-HIV drugs enfuvirtide and albuvirtide were approved for clinical use by the U.S. FDA and CFDA in 2003 and 2018, respectively.
Jing, Pu, Qian, Wang, Shibo, Jiang
openaire +2 more sources